Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24975789 | 1.00 | HPGD (0.41) | HPGDCYP1A2CYP3A4CYP2C9PDE4B | |
| SCHEMBL24975800 | 0.89 | KDM4E (0.46) | HPGDCYP1A2CYP3A4CYP2C9PDE4B | |
| SCHEMBL31428793 | 0.89 | KDM4E (0.46) | HPGDCYP1A2CYP3A4CYP2C9PDE4B | |
| SCHEMBL31428507 | 0.87 | GRM2 (0.47) | HPGDHSP90AA1HSP90AB1ALDH1A1NPC1 | |
| SCHEMBL24975793 | 0.87 | GRM2 (0.47) | HPGDHSP90AA1HSP90AB1ALDH1A1NPC1 | |
| SCHEMBL24975792 | 0.85 | ERN1 (0.47) | HPGDTSHRRAB9AKMT2A | |
| SCHEMBL31428549 | 0.85 | ERN1 (0.47) | HPGDTSHRRAB9AKMT2A | |
| SCHEMBL31428944 | 0.85 | PDCD1 (0.38) | HPGDCYP1A2CYP3A4CYP2C9PDE4B | |
| SCHEMBL31428671 | 0.82 | HPGD (0.50) | HPGDCYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL31428711 | 0.81 | GRM2 (0.51) | HPGDTSHRCNR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HPGD 4233/4885CYP1A2 3982/4885CYP3A4 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.